Genzyme metabolic news
Genzyme began shipments of newly produced Cerezyme imiglucerase made from its Allston, Mass. manufacturing plant. The biotech said that these shipments will provide uninterrupted treatment for the most vulnerable Gaucher's disease patients. It expects all patients to be able to return to their normal treatment regimen next quarter.
Genzyme also reiterated that it will begin shipments of newly produced Fabrazyme agalsidase beta this month; however, it added that the first two bioreactor runs of the Fabry's disease drug produced low yields. The company said it is producing Fabrazyme at a rate of about 70% of expected demand for 2010. Genzyme said initial shipments will meet 30% of demand, the same level it is currently meeting from existing stock, but that it will begin shipping 70-100% of demand in 2Q10. Genzyme plans to provide an update on the Fabrazyme supply in February. ...